Format

Send to

Choose Destination
Antiviral Res. 2015 Sep;121:69-81. doi: 10.1016/j.antiviral.2015.06.014. Epub 2015 Jun 22.

Chronic hepatitis B: A wave of new therapies on the horizon.

Author information

1
Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, PA 18902, USA. Electronic address: tim.block@blumberginstitute.org.
2
Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, PA 18902, USA.
3
University of California, San Francisco, School of Medicine, Departments of Medicine, Epidemiology and Biostatistics, USA.

Abstract

This year marks the 50th anniversary of the discovery of the Australia antigen (Blumberg et al., 1965), which in 1967 was identified to be the hepatitis B virus (HBV) surface antigen. Even though several antiviral medications have been in use for the management of chronic HBV infection for more than 20years, sustained clearance of HBsAg, similar to the sustained viral response (SVR) or cure in chronic hepatitis C, occurs in only a minority of treated patients. Moreover, even after 10years of effective suppression of HBV viremia with current therapy, there is only a 40-70% reduction in deaths from liver cancer. Recent success in developing antivirals for hepatitis C that are effective across all genotypes has renewed interest in a similar cure for chronic HBV infection. In this article, we review a wave of newly identified drug targets, investigational compounds and experimental strategies that are now under clinical evaluation or in preclinical development. The paper forms part of a symposium in Antiviral Research on "An unfinished story: From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B."

KEYWORDS:

Antiviral therapy; Chronic hepatitis B; Clinical trials; Hepatitis B virus

PMID:
26112647
PMCID:
PMC5391532
DOI:
10.1016/j.antiviral.2015.06.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center